

APAP31191-A 072852.0117  
PATENT

A1 36. (AMENDED) The method of Claim 35 wherein the pharmaceutical is selected from the group consisting of colchicine, sulfapyrazone, allopurinol, piroxicam, tolmetin-sodium, idomethacin, ibuprofen, diflunisal, mefenamic acid, and mesalamine, sulindac, sulindac sulfon, salicylic acid and its derivatives thereof.

Please add the following new claims.

88. (NEW) A method comprising:

(a) administration of an oral liquid dosage form comprising:

(i) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, a bile acid conjugated with an amine by an amide linkage, and combinations thereof;

(ii) a second material selected from the group consisting of an aqueous soluble starch conversion product and/or an aqueous soluble non-starch polysaccharide; and

(iii) water,

A2 wherein the first and second materials both remain in solution for all pH values of the solution within a selected range of pI values.

89. (NEW) The method of Claim 88 wherein the dosage form is selected from the group consisting of a syrup, a thick syrup, and a paste.

90. (NEW) The method of Claim 88 wherein the first material is selected from the group consisting of ursodeoxycholic acid, chenodeoxycholic acid, cholic acid, hyodeoxycholic acid, deoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iocholic acid, tauroursodeoxycholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glyoursodeoxycholic acid, taurocholic acid, glyocholic acid, their derivatives at a hydroxyl or carboxylic acid group on the steroid nucleus, their salts, or their conjugates with amines.

NY02:358466.1

APAP31191-A 072852.0117  
PATENT

91. (NEW) The method of Claim 88 wherein the second material is selected from the group consisting of maltodextrin, dextrin, com syrup, corn syrup solid, soluble starch, and dextrans.

92. (NEW) The method of Claim 88 wherein the oral liquid dosage form comprises one or more additional bile acids, aqueous soluble derivatives of bile acid, bile acid salts, and amine-conjugated bile acids conjugated by an amide linkage.

93. (NEW) The method of Claim 88 wherein the oral liquid dosage form additionally comprises a least one additional agent.

94. (NEW) The method of Claim 93 wherein the additional agent is selected from the group consisting of guar gum, pectin, acacia, carrageenan, carboxymethyl cellulose sodium, hydroxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, povidone, tragacanth gum, xanthan gum, and sorbitan ester.

95. (NEW) The method of Claim 88 wherein the oral liquid dosage form additionally comprises at least one pharmaceutical in a pharmaceutically effective amount.

96. (NEW) The method of Claim 95 wherein the pharmaceutical compound is selected from the group consisting of octreotide, sildenafil citrate, calcitriol, dihydrotachysterol, ampomorphine, yohimbin, trazodone, acyclovir, cidofovir, delavirdine-mesylate, didanosine, famciclovir, forscamet sodium, fluorouracil, ganciclovir sodium, idoxuridine, interferon- $\alpha$ ,  $\beta$ ,  $\gamma$ , lamivudine, nevirapine, penciclovir, ribavirin, stavudine, trifludine, valacyclovir-HCl, zalcitabine, zidovudine, indinavir-H<sub>2</sub>SO<sub>4</sub>, ritonavir, nelfinavir-CH<sub>3</sub>SO<sub>3</sub>H, saquinavir-CH<sub>3</sub>SO<sub>3</sub>H, d-penicillamine, chloroquine, hydroxychloroquine, aurothioglucose, gold sodium thiomalate, auranofin levamisole, DTC, isoprinosine, methyl inosine monophosphate, muramyl dipeptide, diazoxide, hydralazine-HCl, minoxidil, dipyridamole, isoxsuprine.HCl, niacin, nylidhn-HCl,

NY02:358466.1

APAP31191-A 072852.0117  
PATENT

Q2 cont  
phentolamine, doxazosin-CH<sub>3</sub>SO<sub>3</sub>H, prazosin-HCl, terazocin-HCl, clonidine-HCl, nifedipine, molsidonine, amiodarone, acetylsalicylic acid, verapamil, diltiazem, nisoldipine, isradipine, bepridil, isosorbide-dinitrate, pentaerythrytol-tetranitrate, nitroglycerin, cimetidine, famotidine, nizatidine, ranitidine, lansoprazole, omeprazole, misoprostol, sucralfate, metoclopramide-HCl, erythromycin, alprostadiol, albuterol, pirbuterol, terbutaline-H<sub>2</sub>SO<sub>4</sub>, salmetrol, aminophylline, dyphylline, ephedrine, ethylnorepinephrine, isoetharine, isoproterenol, metaproterenol, n-drocromil, oxy triphylline, theophylline, bitolterol, fenoterol, budesonide, flunisolide, beclomethasone-dipropionate, fluticasone-propionate, codeine, codeine sulfate, codeine phosphate, dextromethorphan.HBr, triamcinolone-acetonide, montelukast sodium, zafirlukast, zileuton, cromolyn sodium, ipratropium bromide, nedocromil sodium benzonate, diphenhydramine-HCl, hydrocodone-bitartarate, methadone-HCl, morphine sulfate, acetylcysteine, guaifenesin, ammonium carbonate, ammonium chloride, antimony potassium tartarate, glycerin, terpin-hydrate, colfasciril palmitate, atorvastatin-calcium, cervastatin-sodium, fluvastatin-sodium, lovastatin, pravastatin-sodium, simvastatin, picrorrhazia kurrva, andrographis paniculata, mornga oleifera, albizzia lebeck, adhata vasica, curcuma longa, momordica charantia, gymnema sylvestre, terminalia arjuna, azadirachta indica, tinosporia cordifolia, metronidazole, amphotericin B, clotrimazole, fluconazole, haloprogin, ketoconazole, griseofulvin, itraconazole, terbinafin-HCl, econazole-HNO<sub>3</sub>, miconazole, nystatin, oxiconazole-HNO<sub>3</sub>, sulconazole-HNO<sub>3</sub>, cetirizine-2HCl, dexamethasone, hydrocortisone, prednisolone, cortisone, catechin and its derivatives, glycyrrhizin, glycyrrhizic acid, betamethasone, ludrocortisone acetate, flunisolide, fluticasone-propionate, methyl prednisolone, somastostatin, lispro, glucagon, acarbose, chlorpropamide, glipizide, glyburide, metformin-HCl, repaglinide, tolbutamide, colchicine, sulfinpyrazone, allopudnol, piroxicam, toimetin sodium, indomethacin, ibuprofen, diflunisal, mefenamic acid, naproxen, trientine, sulindac, sulindac sulfone, selenium compounds insuline, heparin, ampicillin, amantadine, rimantadine, proinsulin, celecoxib, budesonide, salicylic acid and its derivatives.

97. (NEW) A method of increasing or decreasing the enterohepatic bile acid comprising;

NY02:358466.1

APAP31191-A 072852.0117  
PATENT

- (a) administration of an oral liquid dosage form comprising:
- (i) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, a bile acid conjugated with an amine by an amide linkage, and combinations thereof;
  - (ii) a second material selected from the group consisting of an aqueous soluble starch conversion product and/or an aqueous soluble non-starch polysaccharide; and
  - (iii) water,

wherein the first and second materials both remain in solution for all pH values of the solution within a selected range of pH values.

98. (NEW) The method of Claim 97 wherein the dosage form is selected from the group consisting of a syrup, a thick syrup, and a paste.

99. (NEW) The method of Claim 97 wherein the first material is selected from the group consisting of ursodeoxycholic acid, chenodeoxycholic acid, cholic acid, hyodeoxycholic acid, deoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iocholic acid, tauroursodeoxycholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glyoursodeoxycholic acid, taurocholic acid, glycocholic acid, their derivatives at a hydroxyl or carboxylic acid group on the steroid nucleus, their salts, or their conjugates with amines.

100. (NEW) The method of Claim 97 wherein the second material is selected from the group consisting of maltodextrin, dextrin, corn syrup, corn syrup solid, soluble starch, and dextrans.

APAP31191-A 072852.0117  
PATENT

**101.** (NEW) The method of Claim 97 wherein the oral liquid dosage form comprises one or more additional bile acids, aqueous soluble derivatives of bile acid, bile acid salts, and amine-conjugated bile acids conjugated by an amide linkage.

**102.** (NEW) The method of Claim 97 wherein the oral liquid dosage form additionally comprises a least one additional agent.

**103.** (NEW) The method of Claim 102 wherein the additional agent is selected from the group consisting of guar gum, pectin, acacia, carrageenan, carboxymethyl cellulose sodium, hydroxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, povidone, tragacanth gum, xanthan gum, and sorbitan ester.

*Q2 cont*  
**104.** (NEW) A method for increasing the blood concentration of intact bile acid comprising;

- (a) administration of an oral liquid dosage form comprising:
- (i) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, a bile acid conjugated with an amine by an amide linkage, and combinations thereof;
  - (ii) a second material selected from the group consisting of an aqueous soluble starch conversion product or an aqueous soluble non-starch polysaccharide; and
  - (iii) water,

wherein the first and second materials both remain in solution for all pH values of the solution within a selected range of pH values.

**105.** (NEW) The method of Claim 104 wherein the dosage form is selected from the group consisting of a syrup, a thick syrup, and a paste.

NY02:358466.1

APAP31191-A 072852.0117  
PATENT

106. (NEW) The method of Claim 104 wherein the first material is selected from the group consisting of ursodeoxycholic acid, chenodeoxycholic acid, cholic acid, hyodeoxycholic acid, deoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iocholic acid, tauroursodeoxycholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glyoursodeoxycholic acid, taurocholic acid, glycocholic acid, their derivatives at a hydroxyl or carboxylic acid group on the steroid nucleus, their salts, or their conjugates with amines.

107. (NEW) The method of Claim 104 wherein the second material is selected from the group consisting of maltodextrin, dextrin, corn syrup, corn syrup solid, soluble starch, and dextrans.

108. (NEW) The method of Claim 104 wherein the oral liquid dosage form comprises one or more additional bile acids, aqueous soluble derivatives of bile acid, bile acid salts, and amine-conjugated bile acids conjugated by an amide linkage.

109. (NEW) The method of Claim 104 wherein the oral liquid dosage form additionally comprises a least one additional agent.

110. (NEW) The method of Claim 109 wherein the additional agent is selected from the group consisting of guar gum, pectin, acacia, carrageenan, carboxymethyl cellulose sodium, hydroxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, povidone, tragacanth gum, xanthan gum, and sorbitan ester.

111. (NEW) A method for achieving a  $C_{\max}$  ( $\mu\text{g UDCA/mL}$ ) of from about 4.5 to about 20.4 with a  $T_{\max}$  of less than about 30 minutes comprising:

(a) administration of an oral liquid dosage form comprising:

APAP31191-A 072852.0117  
PATENT

- (i) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, a bile acid conjugated with an amine by an amide linkage, and combinations thereof;
- (ii) a second material selected from the group consisting of an aqueous soluble starch conversion product and/or an aqueous soluble non-starch polysaccharide; and
- (iii) water,

wherein the first and second materials both remain in solution for all pH values of the solution within a selected range of pH values.

112. (NEW) The method of Claim 111 wherein the dosage form is selected from the group consisting of a syrup, a thick syrup, and a paste.

113. (NEW) The method of Claim 111 wherein the first material is selected from the group consisting of ursodeoxycholic acid, ursodeoxycholic acid derivatives at a hydroxyl or carboxylic acid group on the steroid nucleus, ursodeoxycholic acid salts, and ursodeoxycholic acid conjugates with amines.

114. (NEW) The method of Claim 111 wherein the second material is selected from the group consisting of maltodextrin, dextrin, corn syrup, corn syrup solid, soluble starch, and dextrans.

115. (NEW) The method of Claim 111 wherein the oral liquid dosage form comprises one or more additional bile acids, aqueous soluble derivatives of bile acid, bile acid salts, and amine-conjugated bile acids conjugated by an amide linkage.

116. (NEW) The method of Claim 111 wherein the oral liquid dosage form additionally comprises a least one additional agent.

NY02:358466.1

APAP31191-A 072852.0117  
PATENT

117. (NEW) The method of Claim 111 wherein the additional agent is selected from the group consisting of guar gum, pectin, acacia, carrageenan, carboxymethyl cellulose sodium, hydroxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, povidone, tragacanth gum, xanthan gum, and sorbitan ester.

118. (NEW) The method of Claim 111 wherein the oral liquid dosage form additionally comprises at least one pharmaceutical in a pharmaceutically effective amount.

119. (NEW) The method of Claim 118 wherein the pharmaceutical compound is selected from the group consisting of octreotide, sildenafil citrate, calcitriol, dihydrotachysterol, ampomorphine, yohimbin, trazodone, acyclovir, cidofovir, delavirdine-mesylate, didanosine, famciclovir, forscarnet sodium, fluorouracil, ganciclovir sodium, idoxuridine, interferon- $\alpha$ ,  $\beta$ ,  $\gamma$ , lamivudine, nevirapine, penciclovir, ribavirin, stavudine, trifludine, valacyclovir-HCl, zalcitabine, zidovudine, indinavir-H<sub>2</sub>SO<sub>4</sub>, ritonavir, nelfinavir-CH<sub>3</sub>SO<sub>3</sub>H, saquinavir-CH<sub>3</sub>SO<sub>3</sub>H, d-penicillamine, chloroquine, hydroxychloroquine, aurothioglucose, gold sodium thiomalate, auranofin levamisole, DTC, isoprinosine, methyl inosine monophosphate, muramyl dipeptide, diazoxide, hydralazine-HCl, minoxidil, dipyridamole, isoxsuprine.HCl, niacin, nylidhn-HCl, phentolamine, doxazosin-CH<sub>3</sub>SO<sub>3</sub>H, prazosin-HCl, terazocin-HCl, clonidine-HCl, nifedipine, molsidonine, amiodarone, acetylsalicylic acid, verapamil, diltiazem, nisoldipine, isradipine, bepridil, isosorbide-dinitrate, pentaerythrytol-tetranitrate, nitroglycerin, cimetidine, famotidine, nizatidine, ranitidine, lansoprazole, omeprazole, misoprostol, sucralfate, metoclopramide-HCl, erythromycin, alprostadil, albuterol, pirbuterol, terbutaline-H<sub>2</sub>SO<sub>4</sub>, salmetrol, aminophylline, dyphylline, ephedrine, ethynorepinephrine, isoetharine, isoproterenol, metaproterenol, n-docromil, oxy triphyline, theophylline, bitolterol, fenoterol, budesonide, flunisolide, beclomethasone-dipropionate, fluticasone-propionate, codeine, codeine sulfate, codeine phosphate, dextromethorphan.HBr, triamcinolone-acetonide, montelukast sodium, zafirlukast, zileuton, cromolyn sodium, ipratropium bromide, nedocromil sodium benzonate, diphenhydramine-HCl, hydrocodone-bitartarate, methadone-HCl, morphine sulfate, acetylcysteine, guaifenesin, ammonium carbonate, ammonium chloride, antimony potassium

NY02:358466.1



APAP31191-A 072852.0117  
PATENT

02 cont

tartarate, glycerin, terpin-hydrate, colfasciril palmitate, atorvastatin-calcium, cervastatin-sodium, fluvastatin-sodium, lovastatin, pravastatin-sodium, sirvastatin, picrorrhazia kurrva, andrographis paniculata, mornga oleifera, albizzia lebeck, adhata vasica, curcuma longa, momordica charantia, gymnema sylvestre, terminalia arjuna, azadirachta indica, tinospora cordifolia, metronidazole, amphotericin B, clotrimazole, fluconazole, haloprogin, ketoconazole, griseofulvin, itraconazole, terbinafin-HCl, econazole-HNO<sub>3</sub>, miconazole, nystatin, oxiconazole-HNO<sub>3</sub>, sulconazole-HNO<sub>3</sub>, cetirizine-2HCl, dexamethasone, hydrocortisone, prednisolone, cortisone, catechin and its derivatives, glycyrrhizin, glycyrrhizic acid, betamethasone, hydrocortisone acetate, flunisolide, fluticasone-propionate, methyl prednisolone, somastostatin, lispro, glucagon, acarbose, chlorpropamide, glipizide, glyburide, metformin-HCl, repaglinide, tolbutamide, colchicine, sulfinpyrazone, allopurinol, piroxicam, tometin sodium, indomethacin, ibuprofen, diflunisal, mefenamic acid, naproxen, trientine, sulindac, sulindac sulfone, selenium compounds, insulin, heparin, ampicillin, amantadine, rimantadine, proinsulin, celecoxib, budesonide, salicylic acid and its derivatives.

120. (NEW) A method of increasing or decreasing absorption and elimination of intact bile acid comprising;

- (a) administration of an oral liquid dosage form comprising:
- (i) a first material selected from the group consisting of a bile acid, and aqueous soluble derivative of a bile acid, a bile acid salt, a bile acid conjugated with an amine by an amide linkage, and combinations thereof;
  - (ii) a second material selected from the group consisting of an aqueous soluble starch conversion product and/or an aqueous soluble non-starch polysaccharide; and
  - (iii) water,

wherein the first and second materials both remain in solution for all pH values of the solution within a selected range of pH values.

APAP31191-A 072852.0117  
PATENT

121. (NEW) The method of Claim 120 wherein the dosage form is selected from the group consisting of a syrup, a thick syrup, and a paste.

122. (NEW) The method of Claim 120 wherein the first material is selected from the group consisting of ursodeoxycholic acid, chenodeoxycholic acid, cholic acid, hyodeoxycholic acid, deoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iocholic acid, tauroursodeoxycholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glyoursodeoxycholic acid, taurocholic acid, glycocholic acid, their derivatives at a hydroxyl or carboxylic acid group on the steroid nucleus, their salts, or their conjugates with amines.

123. (NEW) The method of Claim 120 wherein the second material is selected from the group consisting of maltodextrin, dextrin, corn syrup, corn syrup solid, soluble starch, and dextrans.

124. (NEW) The method of Claim 120 wherein the oral liquid dosage form comprises one or more additional bile acids, aqueous soluble derivatives of bile acid, bile acid salts, and amine-conjugated bile acids conjugated by an amide linkage.

125. (NEW) The method of Claim 120 wherein the oral liquid dosage form additionally comprises a least one additional agent.

126. (NEW) The method of Claim 125 wherein the additional agent is selected from the group consisting of guar gum, pectin, acacia, carrageenan, carboxymethyl cellulose sodium, hydroxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, povidone, tragacanth gum, xanthan gum, and sorbitan ester.

127. (NEW) The method of Claim 120 wherein the oral liquid dosage form additionally comprises at least one pharmaceutical in a pharmaceutically effective amount.

NY02:358466.1

APAP31191-A 072852.0117  
PATENT

128. (NEW) The method of Claim 127 wherein the pharmaceutical compound is selected from the group consisting of octreotide, sildenafil citrate, calcitriol, dihydroachysterol, ampomorphine, yohimbin, trazodone, acyclovir, cidofovir, delavirdine-mesylate, didanosine, famciclovir, forscamet sodium, fluorouracil, ganciclovir sodium, idoxuridine, interferon- $\alpha$ ,  $\beta$ ,  $\gamma$ , lamivudine, nevirapine, penciclovir, ribavirin, stavudine, trifludine, valacyclovir-HCl, zalcitabine, zidovudine, indinavir-H<sub>2</sub>SO<sub>4</sub>, ritonavir, nelfinavir-CH<sub>3</sub>SO<sub>3</sub>H, saquinavir-CH<sub>3</sub>SO<sub>3</sub>H, d-penicillamine, chloroquine, hydroxychloroquine, aurothioglucose, gold sodium thiomalate, auranofin levamisole, DTC, isoprinosine, methyl inosine monophosphate, muramyl dipeptide, diazoxide, hydralazine-HCl, minoxidil, dipyrindamole, isoxsuprine.HCl, niacin, nylidhn-HCl, phentolamine, doxazosin-CH<sub>3</sub>SO<sub>3</sub>H, prazosin-HCl, terazocin-HCl, clonidine-HCl, nifedipine, molsidonine, amiodarone, acetylsalicylic acid, verapamil, diltiazem, nisoldipine, isradipine, bepridil, isosorbide-dinitrate, pentaerythritol-tetranitrate, nitroglycerin, cimetidine, famotidine, nizatidine, ranitidine, lansoprazole, omeprazole, misoprostol, sucralfate, metoclopramide-HCl, erythromycin, alprostadil, albuterol, pirbuterol, terbutaline-H<sub>2</sub>SO<sub>4</sub>, salmetrol, aminophylline, dyphylline, ephedrine, ethynorepinephrine, isoetharine, isoproterenol, metaproterenol, n-docromil, oxy triphylline, theophylline, bitolterol, fenoterol, budesonide, flunisolide, beclomethasone-dipropionate, fluticasone-propionate, codeine, codeine sulfate, codeine phosphate, dextromethorphan.HBr, triamcinolone-acetonide, montelukast sodium, zafirlukast, zileuton, cromolyn sodium, ipratropium bromide, nedocromil sodium benzonate, diphenhydramine-HCl, hydrocodone-bitartrate, methadone-HCl, morphine sulfate, acetylcysteine, guaifenesin, ammonium carbonate, ammonium chloride, antimony potassium tartarate, glycerin, terpin-hydrate, colfasciril palmitate, atorvastatin-calcium, cervastatin-sodium, fluvastatin-sodium, lovastatin, pravastatin-sodium, simvastatin, picrorrhazia kurrva, andrographis paniculata, momonga oleifera, albizzia lebeck, adhata vasica, curcuma longa, momordica charantia, gymnema sylvestre, terminalia arjuna, azadirachta indica, tinosporia cordifolia, metronidazole, amphotericin B, clotrimazole, fluconazole, haloprogin, ketoconazole, griseofulvin, itraconazole, terbinafin-HCl, econazole-HNO<sub>3</sub>, miconazole, nystatin, oxiconazole-HNO<sub>3</sub>, sulconazole-HNO<sub>3</sub>, cetirizine-2HCl, dexamethasone, hydrocortisone, prednisolone, cortisone, catechin and its derivatives, glycyrrhizin, glycyrrhizic acid, betamethasone, hydrocortisone acetate, flunisolide,

NY02:358466.1

APAP31191-A 072852.0117  
PATENT

fluticasone-propionate, methyl prednisolone, somastostatin, lispro, glucagon, acarbose, chlorpropamide, glipizide, glyburide, metformin-HCl, repaglinide, tolbutamide, colchicine, sulfinpyrazone, allopudnol, piroxicam, toimetin sodium, indomethacin, ibuprofen, diflunisal, mefenamic acid, naproxen, trientine, sulindac, sulindac sulfone, selenium compounds, insulin, heparin, ampicillin, amantadine, rimantadine, proinsulin, celecoxib, budesonide, salicylic acid and its derivatives.

129. (NEW) A method for achieving a  $C_{max}$  ( $\mu\text{g GUDCA/mL}$ ) of from about 0.3 to about 1.6 with a  $T_{max}$  of less than about 3.5 hours comprising:

- (a) administration of an oral liquid dosage form comprising:
- (i) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, a bile acid conjugated with an amine by an amide linkage, and combinations thereof;
  - (ii) a second material selected from the group consisting of an aqueous soluble starch conversion product and/or an aqueous soluble non-starch polysaccharide; and
  - (iii) water,

wherein the first and second materials both remain in solution for all pH values of the solution within a selected range of pH values.

130. (NEW) The method of Claim 129 wherein the dosage form is selected from the group consisting of a syrup, a thick syrup, and a paste.

131. (NEW) The method of Claim 111 wherein the first material is selected from the group consisting of glyoursodeoxycholic acid, glyoursodeoxycholic acid derivatives at a hydroxyl or carboxylic acid group on the steroid nucleus, glyoursodeoxycholic acid salts, and glyoursodeoxycholic acid conjugates with amines.

APAP31191-A 072852.0117  
PATENT

132. (NEW) The method of Claim 129 wherein the second material is selected from the group consisting of maltodextrin, dextrin, com syrup, com syrup solid, soluble starch, and dextrans.

133. (NEW) The method of Claim 129 wherein the oral liquid dosage form comprises one or more additional bile acids, aqueous soluble derivatives of bile acid, bile acid salts, and amine-conjugated bile acids conjugated by an amide linkage.

134. (NEW) The method of Claim 129 wherein the oral liquid dosage form additionally comprises a least one additional agent.

135. (NEW) The method of Claim 134 wherein the additional agent is selected from the group consisting of guar gum, pectin, acacia, carrageenan, carboxymethyl cellulose sodium, hydroxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, povidone, tragacanth gum, xanthan gum, and sorbitan ester,

136. (NEW) The method of Claim 129 wherein the oral liquid dosage form additionally comprises at least one pharmaceutical in a pharmaceutically effective amount,

137. (NEW) The method of Claim 136 wherein the pharmaceutical compound is selected from the group consisting of octreotide, sildenafil citrate, calcitriol, dihydrotachysterol, ampomorphine, yohimbin, trazodone, acyclovir, cidofovir, delavirdine-mesylate, didanosine, famciclovir, forscamet sodium, fluorouracil, ganciclovir sodium, idoxuridine, interferon- $\alpha$ ,  $\beta$ ,  $\gamma$ , lamivudine, nevirapine, penciclovir, ribavirin, stavudine, trifludine, valacyclovir-HCl, zalcitabine, zidovudine, indinavir-H<sub>2</sub>SO<sub>4</sub>, ritonavir, nelfinavir-CH<sub>3</sub>SO<sub>3</sub>H, saquinavir-CH<sub>3</sub>SO<sub>3</sub>H, d-penicillamine, chloroquine, hydroxychloroquine, aurothioglucose, gold sodium thiomalate, auranofin levamisole, DTC, isoprinosine, methyl inosine monophosphate, muramyl dipeptide, diazoxide, hydralazine-HCl, minoxidil, dipyridamole, isoxsuprine.HCl, niacin, nylidhn-HCl,

NY02:358466.1

APAP31191-A 072852.0117

PATENT

phentolamine, doxazosin-CH<sub>3</sub>SO<sub>3</sub>H, prazosin-HCl, terazocin-HCl, clonidine-HCl, nifedipine, molsidonine, amiodarone, acetylsalicylic acid, verapamil, diltiazem, nisoldipine, isradipine, bepridil, isosorbide-dinitrate, pentaerythrytol-tetranitrate, nitroglycerin, cimetidine, famotidine, nizatidine, ranitidine, lansoprazole, omeprazole, misoprostol, sucralfate, metoclopramide-HCl, erythromycin, alprostadiol, albuterol, pirbuterol, terbutaline-H<sub>2</sub>SO<sub>4</sub>, salmetrol, aminophylline, dyphylline, ephedrine, ethylinorepinephrine, isoetharine, isoproterenol, metaproterenol, n-docromil, oxy triphylline, theophylline, bitolterol, fenoterol, budesonide, flunisolide, beclomethasone-dipropionate, fluticasone-propionate, codeine, codeine sulfate, codeine phosphate, dextromethorphan.HBr, triamcinolone-acetonide, montelukast sodium, zafirlukast, zileuton, cromolyn sodium, ipratropium bromide, nedocromil sodium benzonate, diphenhydramine-HCl, hydrocodone-bitartarate, methadone-HCl, morphine sulfate, acetylcysteine, guaifenesin, ammonium carbonate, ammonium chloride, antimony potassium tartarate, glycerin, terpin-hydrate, colfasciril palmitate, atorvastatin-calcium, cervastatin-sodium, fluvastatin-sodium, lovastatin, pravastatin-sodium, simvastatin, picrorrhazia kurtva, andrographis paniculata, mornga oleifera, albizzia lebeck, adhata vasica, curcuma longa, momordica charantia, gymnema sylvestre, terminalia arjuna, azadirachta indica, tinosporia cordifolia, metronidazole, amphotericin B, clotrimazole, fluconazole, haloprogin, ketoconazole, griseofulvin, itraconazole, terbinafin-HCl, econazole-HNO<sub>3</sub>, miconazole, nystatin, oxiconazole-HNO<sub>3</sub>, sulconazole-HNO<sub>3</sub>, cetirizine-2HCl, dexamethasone, hydrocortisone, prednisolone, cortisone, catechin and its derivatives, glycyrrhizin, glycyrrhizic acid, betamethasone, hydrocortisone acetate, flunisolide, fluticasone-propionate, methyl prednisolone, somastostatin, lispro, glucagon, acarbose, chlorpropamide, glipizide, glyburide, metformin-HCl, repaglinide, tolbutamide, colchicine, sulfinpyrazone, allopurinol, piroxicam, tometin sodium, indomethacin, ibuprofen, diflunisal, mefenamic acid, naproxen, trientine, sulindac, sulindac sulfone, selenium compounds, insulin, heparin, ampicillin, amantadine, rimantadine, proinsulin, celecoxib, budesonide, salicylic acid and its derivatives.

138. (NEW) A clear aqueous solution comprising;

NY02:358466.1

APAP31191-A 072852.0117  
PATENT

- Sub B10*
- (i) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, a bile acid conjugated with an amine by an amide linkage, and combinations thereof;
  - (ii) a second material selected from the group consisting of an aqueous soluble starch conversion product and/or an aqueous soluble non-starch polysaccharide; and
  - (iii) water,

wherein the first and second materials both remain in solution for all pH values of the solution within a selected range of pH values.

*139* 139. (NEW) The solution of Claim 138 wherein the dosage form is selected from the group consisting of a syrup, a thick syrup, and a paste.

140. (NEW) The solution of Claim 138 wherein the first material is selected from the group consisting of ursodeoxycholic acid, chenodeoxycholic acid, cholic acid, hyodeoxycholic acid, deoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iocholic acid, tauroursodeoxycholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glyoursodeoxycholic acid, taurocholic acid, glyocholic acid, their derivatives at a hydroxyl or carboxylic acid group on the steroid nucleus, their salts, or their conjugates with amines.

141. (NEW) The solution of Claim 138 wherein the second material is selected from the group consisting of maltodextrin, dextrin, corn syrup, corn syrup solid, soluble starch, and dextrans.

142. (NEW) The solution of Claim 138 wherein the oral liquid dosage form comprises one or more additional bile acids, aqueous soluble derivatives of bile acid, bile acid salts, and amine-conjugated bile acids conjugated by an amide linkage.

APAP31191-A 072852.0117  
PATENT

*Sub B10*

143. (NEW) The solution of Claim 138 wherein the solution is capable of anti-inflammatory activity.

*unprop.*

144. (NEW) The solution of Claim 138 wherein the solution is capable of analgesic activity.

*unprop.*

*2 cont.*

145. (NEW) The solution of Claim 138 wherein the solution is capable of anticonvulsant activity.

*unprop.*

146. (NEW) The solution of Claim 138 wherein the solution is capable of prolonging survival time in hypoxic conditions.

147. (NEW) The solution of Claim 138 wherein the solution is capable of alleviating or ameliorating stomatitis, gingivoglossitis and toothache.

---